Lymphoma (includes NHL, HL, CNS Lymphoma)

Kymriah® (tisagenlecleucel), First-In-Class CAR-T Therapy From Novartis, Receives Second FDA Approval To Treat Appropriate R/R Patients With Large B-cell Lymphoma

(Novartis) May 1, 2018 - Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

read corporate press release

FDA Expands Approval For World's First T-Cell Therapy

(The Philadelphia Inquirer) May 1, 2018 - The world’s first T-cell therapy, Novartis’ Kymriah, received an additional approval Tuesday to treat an aggressive form of lymphoma in adults, a market expansion that will save lives, and make the drug developed with the University of Pennsylvania far more lucrative.

read article

FDA Approves CAR T Therapy for Large B-Cell Lymphoma Developed at University of Pennsylvania

(Penn Medicine) May 1, 2018 - The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, this time for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.

read press release

FDA Rejects Sandoz's Proposed Rituximab Biosimilar

(The Center For Biosimilars) May 2, 2018 - Sandoz has announced that it has received a Complete Response Letter from the FDA for GP2013, its proposed rituximab biosimilar referencing Rituxan.

read article

Genomic Analysis Unravels Complexities Of The Most Common Form Of Lymphoma And Enables Personalized Treatment

(Dana-Farber) Apr 30, 2018 - Genomic analysis by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard now offers a better framework for understanding the disease’s many forms, which will help to predict individual patient outcomes and guide personalized treatment.

read press release

The Million Dollar Cancer Treatment No One Knows How to Pay for

(MSN.com/Wall Street Journal) Apr 26, 2018 - The emergence of genetics-based medicines is pushing the cost of treating certain diseases to new levels, forcing hospitals and health insurers to reckon with how to cover total costs per patient approaching a million dollars.

read article

Epizyme Provides Update Regarding Tazemetostat Clinical Program

(NASDAQ) Apr 23, 2018 - Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, today announced that U.S.-based enrollment of new patients into tazemetostat clinical trials is temporarily on hold.

read article

American Association For Cancer Research To Host First AACR Bladder Cancer Conference In Denver, 2019

(UCCC/Colorado Cancer Blogs) Apr 25, 2018 - In May 2019, for the first time, AACR will hold a conference focused on advances in bladder cancer, titled Bladder Cancer: Transforming the Field.

read article

Diagnosis-to-Treatment Interval Associated With Prognostic Factors in DLBCL

(Journal Of Clinical Pathways) Apr 26, 2018 - A recent study found that diagnosis-to-treatment interval may be linked with prognostic clinical factors and event-free survival in newly diagnosed diffuse large B-cell lymphoma (DLBCL).

read article

New Tool Predicts Deadly Form of Rare Cancer

(Brigham and Women's Hospital) May 9, 2018 - Investigators from Brigham and Women’s Hospital have found that next-generation, high-throughput sequencing of a specific gene is a stronger predictor of which early-stage patients will develop aggressive, progressive mycosis fungoides (MF,) the most common type of cutaneous T cell lymphoma (CTCL, other than any other established factor.

read press release

ASH Policy Statement in Support of Patient Access to Safe and Effective Drugs

(ASH) May 11, 2018 - As an organization of physicians and scientists who care for desperately ill patients, including those with blood cancers such as leukemia, lymphoma, and myeloma, the American Society of Hematology (ASH) is supportive of efforts to provide insurance parity for all approved evidence-based cancer treatments.

read press release

New Regimens Improve Survival for Children and Young Adults With T-Cell Cancers

(2018 ASCO Annual Meeting) May 16, 2018 - In a federally funded, randomized phase III clinical trial performed by the Children’s Oncology Group (COG), 90% of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84% were cancer free.

read press release

Bayer Highlights Latest Oncology Research at ASCO 2018

(Bayer) May 17, 2018 - Clinical research to be presented from Bayer's growing oncology portfolio, including radium Ra 223 dichloride, sorafenib, regorafenib, copanlisib and other pipeline compounds.

read corporate press release

Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings

(Boston Business Journals) May 17, 2018 - Data being presented underscore commitment to improving patient outcomes and care; six Takeda Oncology-sponsored abstracts accepted for presentation at ASCO 2018 and eight abstracts accepted for presentation at EHA 2018.

read article

GRAIL to Present New Data from Circulating Cell-free Genome Atlas (CCGA) Study at 2018 American Society of Clinical Oncology Annual Meeting

(Morningstar) May 16, 2018 - Results show prototype assays detected high mortality cancer types at early stages.

read article

CIBMTR Announces Collaboration with Kite to Track Long-Term Outcomes Data for YESCARTA®

(BeTheMatch.org) May 17, 2018 - A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T cell (CAR T) therapies is formed between the CIBMTR® (Center for International Blood and Marrow Transplant Research®), and Kite, a Gilead Company.

read press release

ASCO’s TAPUR Study Website Now Features Updates on Patient Cohort Expansions and Closures

(ASCO in Action) May 14, 2018 - ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study now provides a full list of patient cohort expansions and closures on its website.

read article

Oncternal Opens its CIRLL Study, a Combination Trial of Cirmtuzumab with Ibrutinib in B-Cell Malignancies

(Morningstar) May 15, 2018 - Oncternal Therapeutics, Inc. today announced its opening of the CIRLL study (Cirmtuzumab and Ibrutinib targeting ROR1 for Lymphoma and Leukemia), a Phase 1b/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell malignancies, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).

read article

Important Update For Healthcare Professionals And Patients Regarding Imbruvica® (Ibrutinib)

(Pharmacyclics) May 11, 2018 - For the past five years, we have been proud to offer IMBRUVICA® (ibrutinib) to patients facing serious blood cancers, such as leukemia and lymphoma. We are privileged and honored to be part of the blood cancer community and we look forward to building on that legacy.

read press release

Novartis Data at ASCO and EHA Reinforce Company's Commitment To Reimagining Cancer

(Novartis) May 17, 2018 - Results from the Kisqali® MONALEESA clinical trial program, the largest industry-sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be presented at ASCO; Long-term analyses of Tasigna® Treatment-free Remission (TFR) studies in Ph+ CML-CP to be featured at both congresses; New 12-month updates from JULIET trial of Kymriah® in relapsed/refractory DLBCL to be presented at EHA.

read corporate press release
Next Page